KINAXO Announces Agreement with Johnson & Johnson Pharmaceutical Research & Development

15-Jan-2007

KINAXO Biotechnologies GmbH announced that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica. Under the agreement, KINAXO will use the KinaTorTM technology to perform target selectivity analyses for selected J&JPRD small molecule compounds.

The KinaTorTM technology uses immobilized small molecule inhibitors to detect their protein binding partners in biological samples. Small molecule-protein interactions are identified by a combination of sophisticated affinity-based separation procedures and sensitive mass spectrometry. The KinaTorTM provides tailor-made solutions for various problems in drug development, such as the identification of previously unknown disease-relevant targets as well as off-target related toxicities.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic World Mass Spectrometry

Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!

3 products
3 brochures
View topic world
Topic World Mass Spectrometry

Topic World Mass Spectrometry

Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!

3 products
3 brochures